Építés alatt – nem éles oldal
Belépés

NCT07637006Toborzás még nem indult2. fázis

Linzhi Jianghuang Fufang Huoxue Anshen Capsule for Non-alcoholic Fatty Liver

The Efficacy and Safety of Linzhi Jianghuang Fufang Huoxue Anshen Capsule for Non-alcoholic Fatty Liver: a Randomized, Double-blinded, Placebo-controlled Trial

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. jún. 9.

Következő lépések

Rövid összefoglaló (regiszter, angolul)

This is a randomized, double-blinded, placebo-controlled clinical trial aimed at evaluating the efficacy and safety of Linzhi Jianghuang Fufang Huoxue Anshen Capsule (LJF) for non-alcoholic fatty liver.

Állapot (regiszter)
Toborzás még nem indult
Fázis (regiszter)
2. fázis
Vizsgálattípus
Beavatkozással járó
Résztvevők száma
180 (tervezett)
Első benyújtás
2026. máj. 28.
Kezdés
2026. szept.
Elsődleges befejezés
2028. júl.
Fő szponzor
Hong Kong Baptist University
NCT-szám
NCT07637006

Mit vállalsz

  • Vizsgálat típusa: Beavatkozással járó · 2. fázis
  • Tervezett résztvevők: 180
  • 2026. szept. és az elsődleges befejezés (2028. júl.) között
  • Nincs megadott helyszín, ország nélkül
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • 9) Use of medications that may cause hepatic steatosis or steatohepatitis (e.g., tamoxifen, amiodarone, glucocorticoids, tetracyclines, methotrexate, valproate, salicylates, estrogens) or potentially hepatotoxic drugs for 2 consecutive weeks or more within the past year;
  • 11) Adjustment of hypoglycemic, antihypertensive, or lipid-lowering medications within the past 3 months (e.g., adding or discontinuing medication, dose change, or irregular use);
  • 12) Regular use of hepatoprotective drugs or vitamin E within the past month;
  • 15) Coagulation abnormalities, or current use of medications or foods with anticoagulant effects (e.g., aspirin, warfarin, Panax notoginseng, safflower, Angelica sinensis, peach kernel, etc.);
  • 16) Concomitant psychiatric or psychological disorders, or substance/drug abuse;
  • 19) Contraindications for MRI examination, such as claustrophobia or presence of metallic implants;

Más betegség

  • 1) Excessive alcohol intake (converted pure alcohol > 210 g per week for men, > 140 g per week for women), or an Alcohol Use Disorder Identification Test (AUDIT) score ≥ 8;
  • 2) Other liver diseases (e.g., alcoholic hepatitis, viral hepatitis, drug-induced liver disease, Wilson's disease, autoimmune liver disease, etc.), or a history of liver transplantation or liver resection;
  • 4) Presence of other endocrine system disorders, such as hyperthyroidism, Cushing's syndrome, etc.;
  • 5) History of malignancy that has not been in complete remission for more than 5 years;
  • 7) Poorly controlled severe hypertension, defined as systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 110 mmHg;
  • 13) History of bariatric surgery within the past year, or body weight change > 5% within the past 3 months;
  • 14) History of surgery within the past month;
  • 17) Known allergic constitution, or known allergy to any component of LJF;

Laborértékek

  • 3) Presence of severe concurrent diseases affecting the heart, brain, hematopoietic system, immune system, or kidneys (BUN > 1.5 × ULN, Cr > ULN);
  • 6) Hepatic decompensation (total bilirubin, platelet count, prothrombin time, albumin > ULN; ALT or AST > 2 × ULN), presence of ascites, varices, or a history of hepatic encephalopathy;
  • 8) Insulin-dependent diabetes mellitus (e.g., type 1 diabetes mellitus, or current use of insulin), or non-insulin-dependent diabetes mellitus with poor glycemic control (HbA1c ≥ 9.5%), or diabetic acute complications, or diabetes with severe chronic complications;

Egyéb

  • 10) Current use or use within the past 3 months of GLP-1 receptor agonists;
  • 18) Participation in another clinical trial within the past month;
  • 20) Individuals of childbearing potential (male or female) with fertility plans; pregnant or lactating women.

Kiket keres a vizsgálat

  • 1) Age between 18 and 65 years (inclusive);
  • 2) Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF) ≥ 10%;
  • 3) Liver stiffness measured by transient elastography < 7.3 kPa;
  • 4) Presence of one or more metabolic risk factors: a. Fasting plasma glucose ≥ 6.1 mmol/L, or 2-hour postprandial glucose ≥ 7.8 mmol/L, or HbA1c ≥ 5.7%, or a history of type 2 diabetes, or HOMA-IR ≥ 2.5; b. Arterial blood pressure ≥ 130/85 mmHg, or receiving antihypertensive medication; c. Fasting serum triglycerides ≥ 1.7 mmol/L;
  • 5) Diagnosis of NAFLD with Phlegm-Stasis Obstructing Collateral pattern according to Traditional Chinese Medicine (TCM) criteria, formulated based on the "Consensus Opinion on Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Non-alcoholic Fatty Liver Disease (2017)": Primary Symptoms: a. Intercostal stabbing or dull pain; b. Palpable abdominal mass (hypochondriac mass); c. Dark or dull complexion; d. Obesity. Secondary Symptoms: a. Epigastric and chest fullness and oppression; b. Expectoration of sputum; c. Poor appetite and aversion to greasy food; d. Heavy sensation in the limbs. Tongue and Pulse: Dark red tongue with ecchymosis, enlarged tongue body with teeth marks, greasy coating; wiry, slippery, or hesitant pulse. Diagnosis can be established with the presence of at least 2 primary symptoms and 1 or 2 secondary symptoms, in conjunction with the tongue and pulse presentation.
  • 6) Understand the trial content thoroughly and voluntarily sign the informed consent form.

Életkor a regiszterben: 18 év – 65 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.